Are We On The Cusp Of Psychedelics Being Used As Treatment for Alzheimer’s?

Psychedelics researchers insist the substances’ microbiological action has the potential to help combat symptoms in Alzheimer’s patients. To be more specific, a growing segment of the medical community believes pyschedelics’ microbiological action has the potential to help offset symptoms within the brains of those who are saddled by this form of dementia in its earliest stages.  This is an important development as the population is aging, meaning Alzheimer’s disease is quickly becoming a public health threat.  

About the Research

The research referenced above is detailed in a paper recently published in Current Topics in Behavioral Sciences.  The paper explains how psychedelics might prove helpful in preventing the degenerative brain disease that is Alzheimer’s disease.  The research sets the stage for additional research in which psychedelics might be used to treat dementia symptoms.  The information contained in the paper is a bullish sign for psychedelics stocks.

In excess of five million adults are living with Alzheimer’s disease in the United States alone.  This figure is poised to increase by 300% across the ensuing three decades.  Sadly, there is no cure for dementia yet psychedelics certainly provide hope.  Dr. Albert Garcia-Romeu and other scientists at Johns Hopkins University insist psychedelics have the potential to mitigate the effects of the mentally deleterious condition on patients as well as society as a whole.

The Potential Role of Psychedelics in Treating Alzheimer’s

There is a considerable overlap between the impact of psychedelic treatment within the brain and the root causes of dementia such as Alzheimer’s disease.  It is possible that a carefully structured regimen of psychedelics will help boost quality of life for those saddled by Alzheimer’s disease.

A UC Davis lab headed by Dr. David Olson has determined psychedelics have a powerful impact on the brain.  Olson’s team has determined psychedelics have a significant impact on the brain’s neuroplastic effects.  In plain terms this means an elevated dose of psychedelics has the potential to help the brain grow and otherwise change.  In particular, the frontal lobe and other areas toward the front of the brain compromised by Alzheimer’s have the potential to grow and improve with the ongoing use of psychedelics.

Researchers have also found psilocybin and LSD have meaningful anti-inflammatory properties.  Garcia-Romeu insists psychedelics’ microbiological action has the potential to help combat Alzheimer’s patients’ brain-based symptoms.

The paper’s authors also delve into pyschedelics’ positive impact on mental health as well as memory.  The researchers highlight how alterations in autobiographical memory amidst the use of psychedelics suggest psilocybin and LSC have the potential to catalyze memory recall as well as the clarity of patients’ life memories.  In plain English, this means the research indicates both LSD and psilocybin have the potential to treat Alzheimer’s disease.

More Clinical Trials are Scheduled

Patients battling Alzheimer’s will be encouraged to learn additional clinical trials will be conducted to determine if psychedelics can help treat patients who have Alzheimer’s disease.  Research on the subject is currently being conducted at Johns Hopkins University.  The research team is administering high and moderate doses of psilocybin across a period of two months and quantifying results in the context of improvement in patient quality of life and mood.  

Stay tuned.  If the results of the research conducted at Johns Hopkins University reveal psychedelics improve both mood and quality of life by a considerable margin, it might not be long until psychedelics investors make a bundle of money with well-timed trades.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More